Skip to main content

Advertisement

Table 1 Baseline characteristics of study subjects

From: Testing for Mycobacterium tuberculosis infection using the QuantiFERON-TB GOLD assay in patients with comorbid conditions in a tertiary care endemic setting

 Overall (n)QFT positive (n)QFT negative (n)P value
Age1495693NS
Sex (female)7728490.75
Sex (male)7228440.75
Lymphopenia*5619370.665
Autoimmune disease707< 0.001
Chronic kidney disease7250.613
Renal transplant2020.331
Malignancy154110.357
Chronic liver disease2020.331
COPD1010.439
Achlasia1100.439
Coronary heart disease1010.439
Diabetes207130.809
Other endocrine disorders1010.439
Epilepsy2110.744
Multiple co-morbids186120.096
No Known comorbids7235370.007
  1. ‘*’ lymphopenia defined as lymphocytes <1500 cells/mm3; ‘QFT’, Quantiferon-Gold in Tube assay (Cellestis, Germany); Cut-off for QFT positive ≥ 0.35 IU/ml.’*’ lymphopenia is defined as lymphocytes <1500 cells/mm3; ‘#’ patients with multiple diseases including, diabetes, chronic liver disease, chronic kidney disease, endocrine disorders (panhypo-pitutiarism, hypothyroidism, thalassemia and malignancy); ‘**’ autoimmune disease includes Rheumatoid arthritis, Systemic Lupus Erythematosis and mixed connective tissue disorders. COPD, chronic obstructive pulmonary disorder. QFT negative and QFT positive groups are compared using Chi-square test. P value ≤ 0.05 is considered to be significant between the two groups.